Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.
USA

Needham reiterates purchase recommendation for Mereo Biopharma Group Plc – ADR (MREO)

Fintel reports that on May 26, 2023, Needham will repeated Mereo Biopharma Group Plc – Scope of ADR (NASDAQ: MREO) with buy recommendation.

Analyst Price Expectations Suggest a 313.08% Gain

One-year average as of May 11, 2023 target price Mereo Biopharma Group Plc – ADR is 4.42. Expectations range from a low of $4.04 to a high of $5.25. The average target price is up 313.08% from the latest reported closing price of 1.07%.

see our corporate leaderboard The target price has the most upside potential.

Mereo Biopharma Group Plc – ADR’s annual revenue was 0MM, down ±%.Non-GAAP Annual Forecast EPS -0.01.

What is Fund Sentiment?

there is 71 foundations or institutions reporting positions At Mereo Biopharma Group Plc – ADR. That’s down 3 owners or 4.05% from the last quarter.Portfolio average weight out of all funds MREO dedicated was 0.05%, down 13.36%. Total shares owned by institutional investors fell by 14.36% to 63,035,000 shares over the past three months. of put/call ratio The MREO is 0.01, indicating a bullish outlook.

What are other shareholders doing?

MREO / Mereo Biopharma Group Plc - ADR shares held by the institution

rubric capital management holds 10,366,000 shares representing an 8.31% ownership interest in the company. There was no change in the last quarter.

Orbimed Advisors owns 7,748,000 shares, representing 6.21% of the company. Earlier filings reported that the company owned 10,606,000 shares. Decrease 36.88%.office Diminished Portfolio allocation to MREO increased by 29.34% QoQ.

Subletta Capital Management holds 7,364,000 shares representing 5.90% ownership of the company. There was no change in the last quarter.

Rock Springs Capital Management holds 6,245,000 shares representing a 5.01% ownership interest in the company. There was no change in the last quarter.

Citadel Advisors holds 3,048,000 shares representing a 2.44% ownership interest in the company. Earlier filings reported that the company owned 3,062,000 shares. Decrease 0.47%.office Diminished Portfolio allocation to MREO increased by 23.36% QoQ.

Mereo Biopharma Group Background Information
(This description was provided by us.)

Mereo BioPharma is a biopharmaceutical company focused on developing and commercializing innovative therapies aimed at improving outcomes in oncology and rare diseases. We have developed a portfolio of six clinical-stage product candidates. Mereo’s lead oncology product candidate, etigilimab (anti-TIGIT), has recently been shown to be effective in three rare tumors and many gynecologic cancers, including cervical and endometrial cancers. The Company’s second oncology product, navicisizumab for the treatment of late-stage ovarian cancer, has completed a Phase 1 trial and is partnering with OncXerna Therapeutics, Inc. (formerly Oncologie, Inc.). The company has two rare disease product candidates. A treatment for severe alpha-1 antitrypsin deficiency (AATD) is being investigated in ongoing Phase 2 demonstration studies in the US and Europe, and the company expects to report topline data in the second half of 2021. be. , and cetolumab for the treatment of osteogenesis imperfecta (OI). In September 2020, the FDA granted Rare Pediatric Disease Designation to cetorsumab for the treatment of OIs. Following the completion of our Phase 2b ASTEROID study, we met with both his FDA and the European Medicines Agency (EMA) to discuss design principles for a single Phase 2/3 pediatric registry study in OI. In December 2020, the company entered into a licensing and collaboration agreement with Ultragenyx Pharmaceutical Inc. for cetorsumab in OI.

This story was originally Fintel.

The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.

Summarize this content to 100 words

Fintel reports that on May 26, 2023, Needham will repeated Mereo Biopharma Group Plc – Scope of ADR (NASDAQ: MREO) with buy recommendation. Analyst Price Expectations Suggest a 313.08% Gain One-year average as of May 11, 2023 target price Mereo Biopharma Group Plc – ADR is 4.42. Expectations range from a low of $4.04 to a high of $5.25. The average target price is up 313.08% from the latest reported closing price of 1.07%.

see our corporate leaderboard The target price has the most upside potential. Mereo Biopharma Group Plc – ADR’s annual revenue was 0MM, down ±%.Non-GAAP Annual Forecast EPS -0.01. What is Fund Sentiment? there is 71 foundations or institutions reporting positions At Mereo Biopharma Group Plc – ADR. That’s down 3 owners or 4.05% from the last quarter.Portfolio average weight out of all funds MREO dedicated was 0.05%, down 13.36%. Total shares owned by institutional investors fell by 14.36% to 63,035,000 shares over the past three months. of put/call ratio The MREO is 0.01, indicating a bullish outlook. What are other shareholders doing? rubric capital management holds 10,366,000 shares representing an 8.31% ownership interest in the company. There was no change in the last quarter. Orbimed Advisors owns 7,748,000 shares, representing 6.21% of the company. Earlier filings reported that the company owned 10,606,000 shares. Decrease 36.88%.office Diminished Portfolio allocation to MREO increased by 29.34% QoQ.

Subletta Capital Management holds 7,364,000 shares representing 5.90% ownership of the company. There was no change in the last quarter. Rock Springs Capital Management holds 6,245,000 shares representing a 5.01% ownership interest in the company. There was no change in the last quarter. Citadel Advisors holds 3,048,000 shares representing a 2.44% ownership interest in the company. Earlier filings reported that the company owned 3,062,000 shares. Decrease 0.47%.office Diminished Portfolio allocation to MREO increased by 23.36% QoQ. Mereo Biopharma Group Background Information(This description was provided by us.)
Mereo BioPharma is a biopharmaceutical company focused on developing and commercializing innovative therapies aimed at improving outcomes in oncology and rare diseases. We have developed a portfolio of six clinical-stage product candidates. Mereo’s lead oncology product candidate, etigilimab (anti-TIGIT), has recently been shown to be effective in three rare tumors and many gynecologic cancers, including cervical and endometrial cancers. The Company’s second oncology product, navicisizumab for the treatment of late-stage ovarian cancer, has completed a Phase 1 trial and is partnering with OncXerna Therapeutics, Inc. (formerly Oncologie, Inc.). The company has two rare disease product candidates. A treatment for severe alpha-1 antitrypsin deficiency (AATD) is being investigated in ongoing Phase 2 demonstration studies in the US and Europe, and the company expects to report topline data in the second half of 2021. be. , and cetolumab for the treatment of osteogenesis imperfecta (OI). In September 2020, the FDA granted Rare Pediatric Disease Designation to cetorsumab for the treatment of OIs. Following the completion of our Phase 2b ASTEROID study, we met with both his FDA and the European Medicines Agency (EMA) to discuss design principles for a single Phase 2/3 pediatric registry study in OI. In December 2020, the company entered into a licensing and collaboration agreement with Ultragenyx Pharmaceutical Inc. for cetorsumab in OI.

This story was originally Fintel.

The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.

https://www.nasdaq.com/articles/needham-reiterates-mereo-biopharma-group-plc-adr-mreo-buy-recommendation-0 Needham reiterates purchase recommendation for Mereo Biopharma Group Plc – ADR (MREO)

Back to top button